Shuttle Pharmaceuticals Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Shuttle Pharmaceuticals Holdings, Inc. on September 4, 2024. The filing serves to disseminate a corporate update regarding the second quarter ended June 30, 2024, following the company's submission of its Quarterly Report on Form 10-Q.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced Form 10-Q and the attached press release (Exhibit 99.1), which are not included in the provided text.
Material Changes
No material changes to financial performance or operations are detailed within the body of this 8-K filing. The document acts solely as a notification of the corporate update issued on the filing date.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, and specific risk factors are not present in this filing text. The report explicitly states that the information in Item 8.01 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings.
Key Facts for Investor Verification
- Verify the specific financial results for the second quarter ended June 30, 2024, by reviewing the attached Press Release (Exhibit 99.1) and the Form 10-Q.
- Confirm the company's status as an emerging growth company, as indicated by the checkmark in the filing.
- Note that the information in this 8-K is not subject to the liabilities of Section 18 of the Exchange Act.
- Review the Form 10-Q for detailed liquidity and capital resource information not present in this summary.